Does pharmacological treatment of neuropsychiatric symptoms in Alzheimers disease relieve caregiver burden?

Drugs and Aging

Volumn 29, Issue 3, 2012, Pages 167-179

  Levy, Karen ^a   Lanctôt, Krista L ^a,b,c   Farber, Shale B ^a   Li, Abby ^a   Herrmann, Nathan ^a,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimers disease; Antidepressants; Antipsychotics; Cholinesterase inhibitors; Elderly; Health care provider; Memantine; Quality of life

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATORVASTATIN; CHOLINESTERASE INHIBITOR; DONEPEZIL; FLUOXETINE; GALANTAMINE; GINKGO BILOBA EXTRACT; HALOPERIDOL; INDOMETACIN; MEMANTINE; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; ROSIGLITAZONE; SERTRALINE; TOPIRAMATE; TRAZODONE;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; CAREGIVER BURDEN; COGNITION; DELUSION; DEMENTIA; DEPRESSION; DISEASE SEVERITY; HALLUCINATION; HUMAN; MAJOR DEPRESSION; PRIORITY JOURNAL; REVIEW;

EID: 84857822268     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11599140-000000000-00000     Document Type: Review

References (72)

1. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: A Delphi consensus study. Lancet 2005 Dec 17; 366 (9503): 2112-7
2. World Alzheimer Report 2009. London: Alzheimer s Disease International, 2009 [online]. Available from URL: Http://www.alz.co.uk/research/world-report [Accessed 2011 Jun]
3. Schulz R, O Brien AT, Bookwala J, et al. Psychiatric and physical morbidity effects of dementia caregiving: Prevalence, correlates, and causes. Gerontologist 1995 Dec; 35 (6): 771-91
4. George LK, Gwyther LP. Caregiver well-being: A multidimensional examination of family caregivers of demented adults. Gerontologist 1986 Jun; 26 (3): 253-9
5. Bergvall N, Brinck P, Eek D, et al. Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer s disease. Int Psychogeriatr 2011 Feb; 23 (1): 73-85
6. Clipp EC, George LK. Psychotropic drug use among caregivers of patients with dementia. J Am Geriatr Soc 1990 Mar; 38 (3): 227-35
7. Vitaliano PP, Zhang J, Scanlan JM. Is caregiving hazardous to one s physical health? A meta-analysis. Psychol Bull 2003 Nov; 129 (6): 946-72
8. Schulz R, Beach SR. Caregiving as a risk factor for mortality: The Caregiver Health Effects Study. JAMA 1999 Dec 15; 282 (23): 2215-9
9. Achterberg W, Pot AM, Kerkstra A, et al. Depressive symptoms in newly admitted nursing home residents. Int J Geriatr Psychiatry 2006 Dec; 21 (12): 1156-62
10. Teresi J, Abrams R, Holmes D, et al. Prevalence of depression and depression recognition in nursing homes. Soc Psychiatry Psychiatr Epidemiol 2001 Dec; 36 (12): 613-20
11. Drageset J, Natvig GK, Eide GE, et al. Differences in health-related quality of life between older nursing home residents without cognitive impairment and the general population of Norway. J Clin Nurs 2008 May; 17 (9): 1227-36
12. Fahey T, Montgomery AA, Barnes J, et al. Quality of care for elderly residents in nursing homes and elderly people living at home: Controlled observational study. BMJ 2003 Mar 15; 326 (7389): 580-3
13. Miller LJ. The use of cognitive enhancers in behavioral disturbances of Alzheimer s disease. Consult Pharm 2007 Sep; 22 (9): 754-62
14. Herrmann N, Lanctôt KL. Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease. Can J Psychiatry 2007 Oct; 52 (10): 630-46
15. Thompson S, Herrmann N, Rapoport MJ, et al. Efficacy and safety of antidepressants for treatment of depression in Alzheimer s disease: A metaanalysis. Can J Psychiatry 2007 Apr; 52 (4): 248-55
16. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002 Mar; 159 (3): 460-5
17. Deeken JF, Taylor KL, Mangan P, et al. Care for the caregivers: A review of self-report instruments developed to measure the burden, needs, and quality of life of informal caregivers. J Pain Symptom Manage 2003 Oct; 26 (4): 922-53
18. Vitaliano PP, Young HM, Russo J. Burden: A review of measures used among caregivers of individuals with dementia. Gerontologist 1991 Feb; 31 (1): 67-75
19. Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer s disease: The Neuropsychiatric Inventory Caregiver Distress scale. J Am Geriatr Soc 1998 Feb; 46 (2): 210-5
20. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994 Dec; 44 (12): 2308-14
21. Kat MG, de Jonghe JF, Aalten P, et al. Neuropsychiatric symptoms of dementia: Psychometric aspects of the Dutch Neuropsychiatric Inventory (NPI) [in Dutch]. Tijdschr Gerontol Geriatr 2002 Sep; 33 (4): 150-5
22. Leung VP, Lam LC, Chiu HF, et al. Validation study of the Chinese version of the neuropsychiatric inventory (CNPI). Int J Geriatr Psychiatry 2001 Aug; 16 (8): 789-93
23. Politis AM, Mayer LS, Passa M, et al. Validity and reliability of the newly translated Hellenic Neuropsychiatric Inventory (H-NPI) applied to Greek outpatients with Alzheimer s disease: A study of disturbing behaviors among referrals to a memory clinic. Int J Geriatr Psychiatry 2004 Mar; 19 (3): 203-8
24. Wood S, Cummings JL, Hsu MA, et al. The use of the neuropsychiatric inventory in nursing home residents: Characterization and measurement. Am J Geriatr Psychiatry 2000 Winter; 8 (1): 75-83
25. Bass DM, McClendon MJ, Deimling GT, et al. The influence of a diagnosed mental impairment on family caregiver strain. J Gerontol 1994 May; 49 (3): S146-55
26. Pearlin LI, Mullan JT, Semple SJ, et al. Caregiving and the stress process: An overview of concepts and their measures. Gerontologist 1990 Oct; 30 (5): 583-94
27. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer s disease. Neurology 2001 Aug 28; 57 (4): 613-20
28. Maas M, Buckwalter KC. Nursing evaluation research: Alzheimer s care unit. Bethesda (MD): National Institute of Health, Center for Nursing Research, 1990
29. Doward LC, McKenna SP, Kohlmann T, et al. The international development of the RGHQoL: A quality of life measure for recurrent genital herpes. Qual Life Res 1998 Feb; 7 (2): 143-53
30. Logsdon RG, Teri L, Weiner MF, et al. Assessment of agitation in Alzheimer s disease: The agitated behavior in dementia scale. Alzheimer s Disease Cooperative Study. J Am Geriatr Soc 1999 Nov; 47 (11): 1354-8
31. Vitaliano PP, Russo J, Young HM, et al. The Screen for Caregiver Burden. Gerontologist 1991 Feb; 31 (1): 76-83
32. Van Der Kam P, Mol F, Wimmers MFHG. Rating scale for elderly patients [in Dutch]. Deventer: Van Loghum Slaterus, 1971
33. Wimo ANG. Validity and reliability of assessments of time: Comparisons of direct observations and estimates of time by the use of the Resource Utilization in Dementia (RUD)- instrument. Arch Gerontol Geriatr 2007; 44 (1): 71-81
34. Davis KL, Marin DB, Kane R, et al. The Caregiver Activity Survey (CAS): Development and validation of a new measure for caregivers of persons with Alzheimer s disease. Int J Geriatr Psychiatry 1997 Oct; 12 (10): 978-88
35. Marin DB, Dugue M, Schmeidler J, et al. The Caregiver Activity Survey (CAS): Longitudinal validation of an instrument that measures time spent caregiving for individuals with Alzheimer s disease. Int J Geriatr Psychiatry 2000 Aug; 15 (8): 680-6
36. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007 Jul 31; 69 (5): 459-69
37. Birks J. Cholinesterase inhibitors for Alzheimer s disease. Cochrane Database Syst Rev 2006; (1): CD005593
38. Cummings JL, McRae T, Zhang R. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry 2006 Jul; 14 (7): 605-12
39. Mega MS, Masterman DM, O Connor SM, et al. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999 Nov; 56 (11): 1388-93
40. Herrmann N, Rabheru K, Wang J, et al. Galantamine treatment of problematic behavior in Alzheimer disease: Post-hoc analysis of pooled data from three large trials.Am J Geriatr Psychiatry 2005 Jun; 13 (6): 527-34
41. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004 Jul 27; 63 (2): 214-9
42. Howard RJ, Juszczak E, Ballard CG, et al. Donepezil for the treatment of agitation in Alzheimer s disease. N Engl J Med 2007 Oct 4; 357 (14): 1382-92
43. Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living in patient with moderate to severe Alzheimer s disease and effect on caregiver burden. J Am Geriatr Soc 2003; 51 (6): 737-44
44. Bullock R, Bergman H, Touchon J, et al. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer s disease. Curr Med Res Opin 2006 Mar; 22 (3): 483-94
45. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer s disease: Rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007 May; 22 (5): 456-67
46. Cummings JL, Schneider L, Tariot PN, et al. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer s disease. Am J Psychiatry 2004 Mar; 161 (3): 532-8
47. Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer s disease. Drugs Aging 2003; 20 (10): 777-89
48. Cummings JL, Schneider E, Tariot PN, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006 Jul 11; 67 (1): 57-63
49. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer s disease. N Engl J Med 2003 Apr 3; 348 (14): 1333-41
50. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer s disease. Int J Geriatr Psychiatry 2004 Feb; 19 (2): 115-26
51. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A doubleblind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000 Oct; 57 (10): 968-76
52. Streim JE, Porsteinsson AP, Breder CD, et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry 2008 Jul; 16 (7): 537-50
53. Sultzer DL, Davis SM, Tariot PN, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer s disease: Phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008 Jul; 165 (7): 844-54
54. Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: A randomized, placebo-controlled clinical trial. Neurology 2000 Nov 14; 55 (9): 1271-8
55. Caligiuri MP, Rockwell E, Jeste DV. Extrapyramidal side effects in patients with Alzheimer s disease treated with low-dose neuroleptic medication. Am J Geriatr Psychiatry 1998; 6 (1): 75-82
56. Rapoport M, Mamdani M, Shulman KI, et al. Antipsychotic use in the elderly: Shifting trends and increasing costs. Int J Geriatr Psychiatry 2005 Aug; 20 (8): 749-53
57. Canadian Adverse Drug Reaction Monitoring Program (CADRMP). Increased mortality associated with the use of atypical antipsychotic drugs in elderly patients with dementia [safety alert]. Ottawa (ON): Health Canada, 2005
58. Valiyeva E, Herrmann N, Rochon PA, et al. Effect of regulatory warnings on antipsychotic prescription ratesamong elderly patients with dementia: A population-based time-series analysis. CMAJ 2008 Aug 26; 179 (5): 438-46
59. Auchus AP, Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer s disease. J Neuropsychiatry Clin Neurosci 1997; 9 (4): 591-3
60. Finkel SI, Mintzer JE, Dysken M, et al. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer s disease in outpatients treated with donepezil. Int J Geriatr Psychiatry 2004 Jan; 19 (1): 9-18
61. Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: Efficacy and safety of sertraline therapy, and the benefits of depression reduction: The DIADS. Arch Gen Psychiatry 2003 Jul; 60 (7): 737-46
62. de Jong D, Jansen R, Hoefnagels W, et al. No effect of oneyear treatment with indomethacin on Alzheimer s disease progression: A randomized controlled trial. PLoS One 2008; 3 (1): E1475
63. Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer s disease: Results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 2010; 30 (2): 131-46
64. Mowla A, Pani A. Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: A double-blind, randomized clinical trial. J Clin Psychopharmacol 2010 Feb; 30 (1): 40-3
65. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: Preliminary results. Arch Neurol 2005 May; 62 (5): 753-7
66. Napryeyenko O, Sonnik G, Tartakovsky I. Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: Analyses of a randomised controlled trial. J Neurol Sci 2009 Aug 15; 283 (1-2): 224-9
67. Freund-Levi Y, Basun H, Cederholm T, et al. Omega-3 supplementation in mild to moderate Alzheimer s disease: Effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 2008 Feb; 23 (2): 161-9
68. Given CW, Given B, Stommel M, et al. The caregiver reaction assessment (CRA) for caregivers to persons with chronic physical and mental impairments. Res Nurs Health 1992 Aug; 15 (4): 271-83
69. Pitfield C, Shahriyarmolki K, Livingston G. A systematic review of stress in staff caring for people with dementia living in 24-hour care settings. Int Psychogeriatr 2011 Feb; 23 (1): 4-9
70. Schoenmakers B, Buntinx F, De Lepeleire J. Can pharmacological treatment of behavioural disturbances in elderly patients with dementia lower the burden of their family caregiver? Fam Pract 2009 Aug; 26 (4): 279-86
71. Pearson J, Verma S, Nellett C. Elderly psychiatric patient status and caregiver perceptions as predictors of caregiver burden. Gerontologist 1988 Feb; 28 (1): 79-83
72. Wood SA, Cummings JL, Barclay T, et al. Assessing the impact of neuropsychiatric symptoms on distress in professional caregivers. Aging Mental Health 1999; 3 (3): 241-5